These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

831 related articles for article (PubMed ID: 11284186)

  • 21. A case for the antenatal administration of anti-D immunoglobulin to primigravidae.
    Tovey LA; Taverner JM
    Lancet; 1981 Apr; 1(8225):878-81. PubMed ID: 6112301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prenatal diagnosis and prevention of hemolytic disease of newborn].
    Fischer K
    Infusionsther Transfusionsmed; 1993 Jun; 20 Suppl 2():64-9. PubMed ID: 8374293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for the protective effect of maternal FcR-blocking IgG alloantibodies HLA-DR in Rh D-haemolytic disease of the newborn.
    Dooren MC; van Kamp IL; Kanhai HH; Gravenhorst JB; von dem Borne AE; Engelfriet CP
    Vox Sang; 1993; 65(1):55-8. PubMed ID: 8362515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Haemolytic disease of the newborn--from a mother with anti-Kell, anti-E and anti-Vel anti-erythrocyte alloantibodies].
    Vućinović M; Jadrić H; Karelović D; Roje D; Haspl-Hundrić Z; Hrgović Z; Vućinović Z
    Z Geburtshilfe Neonatol; 2004 Oct; 208(5):197-202. PubMed ID: 15508054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The first Rh-isoimmunized pregnancy.
    Goplerud CP; White CA; Bradbury JT; Briggs TL
    Am J Obstet Gynecol; 1973 Mar; 115(5):632-8. PubMed ID: 4631677
    [No Abstract]   [Full Text] [Related]  

  • 26. [Antenatal treatment of maternal-fetal Rh incompatibility hemolysis disease].
    Zhao L; Huang X; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 1998 Jul; 33(7):406-8. PubMed ID: 10806699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative and functional asessment of anti-RhD: a comparative study of non-invasive methods in antenatal prediction of Rh hemolytic disease.
    Filbey D; Garner SF; Hadley AG; Shepard SL
    Acta Obstet Gynecol Scand; 1996 Feb; 75(2):102-7. PubMed ID: 8604593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prenatal typing of fetal DNA in cases of potential alloimmune haemolytic disease of the newborn: clinical benefit outweighs disadvantage.
    Shields JA
    Br J Biomed Sci; 1999; 56(1):49-55. PubMed ID: 10492915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Perinatal hemolytic disease. Part 2: Prevention and management].
    Hohlfeld P; Wirthner D; Tissot JD
    J Gynecol Obstet Biol Reprod (Paris); 1998 Apr; 27(3):265-76. PubMed ID: 9648004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis.
    Kumpel BM
    Transfusion; 2006 Sep; 46(9):1652-6. PubMed ID: 16965599
    [No Abstract]   [Full Text] [Related]  

  • 31. [New possibilities in diagnosing hemolytic disease of newborn infants].
    Fischer K; Poschmann A; Grundmann A; Asmussen S
    Beitr Infusionsther; 1992; 30():431-5. PubMed ID: 1284753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunologic basis and immunoprophylaxis of RhD induced hemolytic disease of the newborn (HDN).
    Payam Khaja Pasha R; Shokri F
    Iran J Immunol; 2008 Dec; 5(4):189-200. PubMed ID: 19098362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Management of feto-maternal red cell allo-immunizations].
    Bricca P; Guinchard E; Guitton Bliem C
    Transfus Clin Biol; 2011 Apr; 18(2):269-76. PubMed ID: 21397546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Haemolytic disease of the fetus and newborn/HDFN/timing in pregnant women and prophylaxis].
    Kulinska R
    Akush Ginekol (Sofiia); 2014; 53(2):58-63. PubMed ID: 25098112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of haemolytic disease of the newborn due to anti-D.
    Tovey G; Wagstaff W
    Br Med J (Clin Res Ed); 1981 Jul; 283(6284):142. PubMed ID: 6266575
    [No Abstract]   [Full Text] [Related]  

  • 36. Severe Rh(D) immunization: anti-D quantitation and treatment possibilities during pregnancy and after birth.
    Gottvall T; Hildén JO; Nelson N; Filbey D
    Acta Paediatr; 1995 Nov; 84(11):1315-7. PubMed ID: 8580635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fetal hemolytic disease due to anti-Rh17 alloimmunization.
    Hirose M; Nakanishi K; Kaku S; Moro H; Hodohara K; Aotani H; Takebayashi K; Noda Y
    Fetal Diagn Ther; 2004; 19(2):182-6. PubMed ID: 14764967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Adverse effects and patient information].
    Cortey A; Brossard Y
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S112-1S118. PubMed ID: 16495836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Haemolytic disease of the new-born by blood-factor incompatibility other than Rh(d) and ABO (author's transl)].
    Schellong G; Sandmann G; Fischer K; Poschmann A
    Dtsch Med Wochenschr; 1976 Oct; 101(44):1591-7. PubMed ID: 824115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prenatal and perinatal immunohematology: recommendations for serologic management of the fetus, newborn infant, and obstetric patient.
    Judd WJ; Luban NL; Ness PM; Silberstein LE; Stroup M; Widmann FK
    Transfusion; 1990 Feb; 30(2):175-83. PubMed ID: 2154871
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.